Our Focus
Target ALS funds investigators who collaborate across scientific disciplines and research constituencies to drive medical breakthroughs for the treatment of ALS.
By bringing together the right people, funding, tools, and resources, Target ALS is breaking down barriers that have existed for decades, amplifying and accelerating the ALS drug discovery and development process.
Our funding opportunities are open to investigators working worldwide.
Our Grantmaking Process
Open Funding Opportunities
In Vivo Target Validation
Proposals due May 10, 2024
Biomarker Consortia
LOIs due May 29, 2024
Recently Closed Funding Opportunities
Upcoming Funding Opportunities
Each year, the Target ALS team strategically designs funding opportunities to accelerate ALS research. We have scheduled the following grants calls for 2024. More details will become available as we approach the announcement date for each call.
- In Vivo Target Validation 2 (AAV C9) | June 2024
- We have partnered with Jackson Laboratories to enable evaluation of novel therapeutics for target engagement and disease-modifying potential in a mammalian model of ALS (C9 G4C2 AAV). Academic and industry labs are encouraged to apply.
Participate in the Target ALS Mission
We encourage you to join our mission by using our core facilities or contacting us to discuss how we can help facilitate your work on ALS. To learn about our current and former grant recipients, visit our Funded Consortia page.
To stay up-to-date with Target ALS announcements, breaking news, and research articles, you can join our newsletter and follow us on LinkedIn.